Feasibility of a standardized three-dose intravenous tranexamic acid protocol in bariatric surgery: a pilot study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Pilot Evaluation of a Standardized Three-Dose Intravenous Tranexamic Acid Regimen for Bariatric Surgery

  • By

  • Paola Llamuca-Castro

  • Diego Lima

  • Arturo Estrada

  • Jason Xia

  • Yeisson Rivero-Moreno

  • Raquel Nogueira

  • Ya Zhou

  • Tiwalade Adediji

  • Joseph Vazzana

  • Diego Camacho

  • Jenny Choi

  • Erin Moran-Atkin

  • October 7, 2026

Share

  • 1

    This prospective pilot cohort assessed implementation of a standardized three-dose intravenous tranexamic acid regimen in metabolic bariatric surgery.

  • 2

    The study included 1,077 patients at one academic center, assigned by alternating 3-month periods to tranexamic acid (549) or no tranexamic acid (528).

  • 3

    The regimen consisted of three 1-g intravenous doses at anesthesia induction, the evening of surgery, and the following morning.

  • 4

    Both groups received the same perioperative thromboprophylaxis, including inpatient unfractionated heparin and 14 days of postdischarge enoxaparin.

  • 5

    Feasibility measures included recruitment, protocol adherence, and 30-day follow-up; exploratory outcomes included clinically significant bleeding, operative time, length of stay, and thromboembolism.

Original Source(s)

Feasibility of a standardized three-dose intravenous tranexamic acid protocol in bariatric surgery: a pilot study

  • by Paola Llamuca-Castro, Diego Lima, Arturo Estrada, Jason Xia, Yeisson Rivero-Moreno, Raquel Nogueira, Ya Zhou, Tiwalade Adediji, Joseph Vazzana, Diego Camacho, Jenny Choi, Erin Moran-Atkin

  • October 7, 2026

Related Content

Resection zone prediction for parenchyma-sparing hepatectomy planning: a comparative study of three modeling paradigms

FDA expands bladder cancer therapy approval

The expansion offers another treatment option for patients with high-grade tumors following BCG failure.

Precision Treatment, Earlier Molecular Detection and De-escalation Transforming Breast Cancer Care

Breast cancer management is becoming increasingly biology-driven, with treatment decisions extending well beyond anatomic stage and conventional receptor classification.

  • by

  • October 14, 2026

  • 6 min